Le Lézard21h
Mitsubishi Tanabe Pharma America to Showcase New Research Findings in ALS at 2025 MDA Clinical and Scientific Conference
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025 Muscular Dystrophy Association ...
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...
ALS News Today1d
Pathmaker wins 3 new patents for neuromodulation technology in ALS
Pathmaker's MyoRegulator is designed to ease hyperexcitability and delivers an electrical current to the spinal cord and ...
Regina woman is living proof of 'breakthrough' ALS drug now approved in Canada
A Regina mother who was one of the first ALS patients to test a new treatment is now celebrating its accelerated approval in ...
Medscape3d
Simple Algorithm Reduces Racial Disparities in MS
A simple treatment algorithm to aid in the selection of appropriate DMTs reduces racial disparities in patients with ...